Breaking News Instant updates and real-time market news.

ALXN

Alexion

$116.41

-0.67 (-0.57%)

, ALNY

Alnylam

$76.83

-1.25 (-1.60%)

04:55
10/28/18
10/28
04:55
10/28/18
04:55

American Society of Nephrology to hold a conference

ASN Kidney Week 2018 will be held in San Diego, CA on October 23-28.

ALXN

Alexion

$116.41

-0.67 (-0.57%)

ALNY

Alnylam

$76.83

-1.25 (-1.60%)

AMGN

Amgen

$185.91

-2.07 (-1.10%)

AZN

AstraZeneca

$37.90

0.125 (0.33%)

BAX

Baxter

$67.14

-0.7 (-1.03%)

BAYRY

Bayer

$0.00

(0.00%)

DRNA

Dicerna

$13.00

(0.00%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FOLD

Amicus

$11.58

0.63 (5.75%)

GSK

GlaxoSmithKline

$39.32

-0.2 (-0.51%)

KERX

Acquired by AKBA 12/18

$3.02

-0.03 (-0.98%)

MNK

Mallinckrodt

$25.61

-0.31 (-1.20%)

NXTM

NxStage Medical

$27.89

0.03 (0.11%)

OMER

Omeros

$16.17

-0.18 (-1.10%)

QDEL

Quidel

$62.64

-1 (-1.57%)

RGLS

Regulus

$1.90

-0.1 (-5.00%)

RTRX

Retrophin

$24.99

0.32 (1.30%)

AKBA

Akebia

$8.06

-0.06 (-0.74%)

SNY

Sanofi

$42.62

-0.45 (-1.04%)

  • 28

    Oct

  • 29

    Oct

  • 30

    Oct

  • 31

    Oct

  • 31

    Oct

  • 01

    Nov

  • 06

    Nov

  • 06

    Nov

  • 07

    Nov

  • 09

    Nov

  • 12

    Nov

  • 13

    Nov

  • 27

    Nov

  • 28

    Jan

  • 18

    Feb

  • 22

    Mar

  • 28

    Apr

ALXN Alexion
$116.41

-0.67 (-0.57%)

09/28/18
LEHM
09/28/18
NO CHANGE
Target $175
LEHM
Overweight
Alexion price target raised to $175 from $165 at Barclays
Barclays analyst Geoff Meacham raised his price target for Alexion Pharmaceuticals to $175 saying this week's positive Phase 3 of Soliris data in neuromyelitis optica spectrum disorder "was a positive surprise for many and is the latest in a string of 'wins' for the company." The analyst thinks Alexion remains one of the more compelling names in biotech and he keeps an Overweight rating on the shares.
10/15/18
PIPR
10/15/18
NO CHANGE
PIPR
Piper lists names to own in Biopharma after recent selloff
Piper Jaffray's biopharma analyst team highlighted names to own in the Biopharma sector following the recent selloff of the broader market. The firm's ideas include: Adamas Pharmaceuticals (ADMS), Agios Pharmaceuticals (AGIO), Agios Pharmaceuticals (ALNY), Alexion (ALXN), Bluebird Bio (BLUE), BioMarin (BMRN), CymaBay (CBAY), Crispr Therapeutics (CRSP), Global Blood Therapeutics (GBT), Horizon Pharma (HZNP), Jazz Pharmaceuticals (JAZZ), Ocular Therapeutix (OCUL), Rigel Pharmaceuticals (RIGL) and Xencor (XNCR).
10/10/18
10/10/18
UPGRADE

Strong Buy
RA Pharmaceuticals upgraded to Strong Buy ahead of Phase 2 data at Raymond James
As previously reported, Raymond James upgraded RA Pharmaceuticals (RARX) to Strong Buy from Outperform with a $28 price target. Analyst Steven Seedhouse expects Phase 2 data for lead subcutaneous C5 inhibitor zilucoplan in generalized myasthenia gravis expected around YE18 to demonstrate a treatment benefit in a mixed refractory/non-refractory patient population and be competitive with Alexion's (ALXN) Soliris. Seedhouse believes a positive Phase 2 readout could be worth $1B in market cap at least and could treat a broader population of patients than Soliris given subcutaneous administration and pricing leverage.
10/24/18
PIPR
10/24/18
NO CHANGE
Target $177
PIPR
Overweight
Piper 'perplexed' by Alexion earnings selloff, says buy shares
Piper Jaffray analyst Christopher Raymond recommends using the selloff today in shares of Alexion Pharmaceuticals (ALXN) as a buying opportunity. The company reported "yet another strong beat/raise quarter and continued impressive pipeline progress," Raymond tells investors in a research note. The analyst sees "little to quibble with commercially" with Soliris' "continued strength and a rapidly expanding margin profile." Raymond is "perplexed" by the stock pullback and keeps an Overweight rating on Alexion with a $177 price target. The stock could be weak on fears over Roche's (RHHBY) update on RG6107, the analyst adds. He says Alexion remains one of his favorite large caps to own "well into 2019."
ALNY Alnylam
$76.83

-1.25 (-1.60%)

10/16/18
NOMU
10/16/18
NO CHANGE
Target $73
NOMU
Reduce
Alnylam rolling submission riskier than prior plans, says Nomura Instinet
Nomura Instinet analyst Christopher Marai says the rolling submission of a new drug application for givosiran that Alnylam Pharmaceuticals announced yesterday pushes back his expected approval timing of mid-2019.The failure to proceed with accelerated approval based on alpha-lipoic acid lowering as a surrogate means that success depends on decreases in annualized attack rates, a much more variable endpoint, Marai tells investors in a research note. He believes the rolling submission is riskier than Alnylam's prior plans and keeps a Reduce rating on the shares with a $73 price target.
10/08/18
GSCO
10/08/18
NO CHANGE
Target $36
GSCO
Sell
Ionis' Tegsedi to face commercial headwinds, says Goldman Sachs
After the FDA approved Ionis (IONS) and affiliate Akcea Therapeutics' (AKCA) Tegsedi for adult polyneuropathy of hereditary transthyretin-mediated amyloidosis, but with a black box warning, Goldman Sachs analyst Salveen Richter said he believes the drug faces commercial headwinds. He cites the underlying safety profile and requirement for consistent monitoring as well as the recent launch of Alnylam's (ALNY) Onpattro and expected launch of Pfizer's (PFE) tafamidis in the first half of 2019. Richter keeps a Sell rating on Ionis shares with a price target of $36.
10/08/18
CANT
10/08/18
INITIATION
Target $135
CANT
Overweight
Cantor reiterates Overweight on Alnylam after Akcea, Ionis win approval
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating on Alnylam Pharmaceuticals (ALNY) with a $135 price target after the FDA approved Tegsedi, to be marketed by Akcea Therapeutics (AKCA). The analyst says that while the approval introduces another competitor to the market, she still expects Alnylam's Onpattroto be able to take significant share in the polyneuropathy hATTR market. Young thinks the Tegsedi label is more onerous and currently models a 60% peak share to Alnylam, a 25% share to Tegsedi and 15% to future competition.
AMGN Amgen
$185.91

-2.07 (-1.10%)

09/19/18
LEER
09/19/18
NO CHANGE
LEER
Outperform
Leerink 'incrementally positive on state of generics industry following meetings
Leerink analyst Ami Fadia tells investors in a research note that she is "incrementally positive" on the state of the generics industry following investor meetings with the management teams from Outperform-rated Amneal (AMRX), Pfenex and Teligent. Fadia says a key takeaway from the teams is that the FDA is placing additional emphasis on reviewing and approving complex generics, and while there is starting to be more first-to-market approvals, there are also more approvals for the second and third generic entrants. Additionally, Fadia says the complex generic opportunity will likely be characterized by a slower-than-typical launch ramp, but also extended duration of meaningful financial contribution due to less overall competitors vs that for oral-solid generics and that while companies still regard biosimilar assets as attractive, the low penetration for biosimilar Remicade in the U.S., Mylan's (MYL) slow start with Fulphila and extended litigation timelines mean management teams looking to participate in this space are taking a more prudent approach and minimizing their upfront investment.
10/25/18
MSCO
10/25/18
NO CHANGE
Target $212
MSCO
Overweight
Repatha list price cut has benefits for Amgen, says Morgan Stanley
Morgan Stanley analyst Matthew Harrison noted that Amgen announced that it is reducing Repatha's list price by 60%, stating that he believes the new list price of $5,850/year is similar to the current net price for the treatment. He also noted that Amgen management said they anticipate little impact to long-term blended net price, though there could be some volatility in the near-term. Given the current political environment, he sees two key benefits to the strategy, namely that it is "a novel SKU strategy" and second the lower price likely improves a structural headwind since Repatha is largely a Medicare product. Harrison keeps an Overweight rating on Amgen shares.
10/01/18
CANT
10/01/18
INITIATION
Target $223
CANT
Neutral
Amgen initiated with a Neutral at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young started Amgen with a Neutral rating and $223 price target.
09/28/18
WELS
09/28/18
NO CHANGE
WELS
Market Perform
Lilly's migraine treatment approval adds to Teva worries, says Wells Fargo
Wells Fargo analyst David Maris noted that Eli Lilly (LLY) received FDA approval of Emgality for the prevention of migraines and announced a U.S. list price of $6,900 annually, which is in line with Teva's (TEVA) Ajovy and Aimovig from Amgen (AMGN) and Novartis (NVS). Lilly's approval adds to Teva investor worries, said Maris, who sees migraines being a competitive market with similar drugs "where the competitors are marketing powerhouses...and Teva is undergoing a lot of organizational change." He maintains a Market Perform rating on Teva shares.
AZN AstraZeneca
$37.90

0.125 (0.33%)

10/25/18
WELS
10/25/18
NO CHANGE
WELS
Wells Fargo says Trump speech today won't be end of drug pricing proposals
Wells Fargo analyst David Maris notes that Politico and other media outlets are reporting that President Donald Trump will propose several new initiatives to address high drug prices when he speaks later today at the U.S. Department of Health and Human Services. Maris thinks Trump's focus will be on how other countries are "freeloading" on U.S. innovation with lower negotiated pricing, stating that news reports make it appear that the administration is targeting the industry for action, rather than other countries to raise their spending. While Maris acknowledges the timing of the speech being near the mid-term elections, he believes these proposals are simply the follow-though of earlier promises. He also expects this is not the end of proposals to address the issue of U.S. drug pricing. Publicly traded large-cap drugmakers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/24/18
CANT
10/24/18
NO CHANGE
Target $68
CANT
Overweight
Cantor Fitzgerald sees nothing fundamental for Tesaro weakness
Cantor Fitzgerald analyst Alethia Young reiterates an Overweight rating and $68 price target on Tesaro's (TSRO) shares as she sees nothing fundamental on recent weakness. While she acknowledges that the stock is down around 28% since ESMO, the analyst pointed out that the AstraZeneca's (AZN) SOLO1 data is a positive read for the niraparib PRIMA study that will read out in 2H 2019. Further, Young believes that key catalysts for Tesaro remain SITC - GARNET and AMBER data, pivotal data in endometrial for its PD-1 licensed from AnaptysBio (ANAB), and PRIMA data in first line ovarian in 2H 2019.
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Outperform
AstraZeneca reinitiated with an Outperform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated AstraZeneca with an Outperform.
10/22/18
CANT
10/22/18
NO CHANGE
Target $68
CANT
Overweight
Tesaro price target raised to $68 from $57 at Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young raised her price target for Tesaro (TSRO) to $68 saying AstraZeneca's (AZN) presented the Solo1 study using olaparib as a first-line treatment for BRCA ovarian cancer patients is positive for Tesaro's first-line study Prima study, with data expected in the second half of 2019. AstraZeneca's data clearly support broad use in first-line "at least" for BRCA ovarian cancer patients, which is positive for the PARP inhibitor class, Young tells investors in a research note. The analyst increased PARP inhibitor penetration in the BRCA patient at peak to 75% from 65% and reiterates an Overweight rating on Tesaro.
BAX Baxter
$67.14

-0.7 (-1.03%)

10/09/18
SBSH
10/09/18
NO CHANGE
SBSH
Citi more selective on Medical Device stocks into Q3 results
Citi analyst Amit Hazan is "much more selective than usual" on Medical Device stocks into the Q3 earnings season. While easier comps should bring "strong and stable" Q3 organic sales growth, recent currency volatility will limit both earnings upside and guidance raises, Hazan tells investors in a research note. He sees only Boston Scientific (BSX) and Intuitive Surgical (ISRG) shares moving higher on earnings reports. The analyst expects volatility in both Becton Dickinson (BDX) and Varian Medical (VAR), but would be an "aggressive" buyer of the stocks on any post-earnings weakness. Hazan is also more cautious on names like Edwards Lifesciences (EW), Baxter (BAX), and Zimmer Biomet (ZBH) into the Q3 prints.
10/15/18
LEHM
10/15/18
INITIATION
LEHM
Underweight
Baxter initiated with an Underweight at Barclays
Barclays analyst Kristen Stewart initiated Baxter with an Underweight rating and $73 price target.
10/16/18
LEHM
10/16/18
INITIATION
LEHM
Barclays starts MedTech sector with Positive view
Barclays analyst Kristen Stewart last night initiated coverage of the MedTech sector with a Positive view. The analyst expects the MedTech market to grow 4%-5% "for the foreseeable future" and believes the recent increase in price-to-earnings multiples in the space is warranted given the improving fundamentals. Looking ahead, she thinks relative P/E multiples "should be at least maintained." Stewart initiated coverage on 12 stocks, with Overweight ratings on Abbott (ABT), Boston Scientific (BSX) Stryker (SYK) and Medtronic (MDT). The analyst put Underweight ratings on Baxter (BAX), Edwards Lifesciences (EW) and Zimmer Biomet (ZBH).
10/16/18
10/16/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Abbott (ABT), Boston Scientific (BSX), Stryker (SYK), and Medtronic (MDT) were initiated with an Overweight at Barclays, while Baxter (BAX), Edwards Lifesciences (EW), and Zimmer Biomet (ZBH) were initiated with an Underweight. 2. Expedia (EXPE) was initiated with an Outperform at Evercore ISI, while TripAdvisor (TRIP) was initiated with an In Line, and Booking Holdings (BKNG) was initiated with an In Line. 3. Facebook (FB) was initiated with a Buy at Loop Capital and Rosenblatt. 4. Snap (SNAP) initiated with a Hold at Loop Capital. 5. VF Corp. (VFC) initiated with a Neutral at Wedbush. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
BAYRY Bayer
$0.00

(0.00%)

09/20/18
SBSH
09/20/18
UPGRADE
SBSH
Buy
Bayer upgraded to Buy from Neutral at Citi
Citi analyst Peter Verdult upgraded Bayer to Buy saying the current risk/reward is "difficult to ignore" with investor sentiment at "rock bottom." The analyst believes the negative earnings revisions have likely bottomed out.
09/18/18
09/18/18
UPGRADE

Bayer upgraded to Buy from Hold at M.M. Warburg
M.M. Warburg analyst Ulrich Huwald upgraded Bayer to Buy and raised his price target for the shares to EUR 88.50 from EUR 85.
09/11/18
EXAN
09/11/18
DOWNGRADE
EXAN
Neutral
Bayer downgraded to Neutral from Outperform at Exane BNP Paribas
08/27/18
08/27/18
UPGRADE
Target $34

Neutral
Portola Pharmaceuticals upgraded to Neutral as MARINER sinks at Credit Suisse
As previously reported, Credit Suisse analyst Vamil Divan upgraded Portola Pharmaceuticals (PTLA) to Neutral from Underperform after Johnson & Johnson (JNJ)/Bayer (BAYRY) presented disappointing data for Xarelto in the acute medically ill population at ESC. The analyst notes that the data avoids a worst case scenario for Portola's Bevyxxa by essentially removing a potentially strong competitor, but does put the pressure on Portola to successfully change medical practice on its own, without help from a larger player such as Johnson & Johnson. Divan also raised his price target on Portola's shares to $34 from $28.
DRNA Dicerna
$13.00

(0.00%)

09/13/18
SBSH
09/13/18
INITIATION
Target $27
SBSH
Buy
Citi starts Dicerna with Buy rating, $27 price target
Citi analyst Robyn Karnauskas initiated coverage of Dicerna Pharmaceuticals with a Buy rating and $27 price target. The analyst sees upside potential of up to three times the current price, and downside risk to the company's cash levels, on success in primary hyperoxaluria. The analyst calls her risk/reward conservative because she assigns 50% probability to primary hyperoxaluria Type 1 and 2. At 100% probability his price target would be $58. Hepatitis B virus is upside to her current model, Karnauskas points out.
09/13/18
09/13/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Weight Watchers (WTW) initiated with an Equal Weight at Morgan Stanley. 2. AMSC (AMSC) initiated with a Buy at Craig-Hallum. 3. AudioEye (AEYE) initiated with a Buy at B. Riley FBR. 4. Lamar Advertising (LAMR) initiated with an Outperform at Imperial Capital. 5. Dicerna (DRNA) initiated with a Buy at Citi. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/18
RILY
09/17/18
NO CHANGE
Target $10
RILY
Neutral
Dicerna shares are 'priced for perfection,' says B. Riley FBR
B. Riley FBR analyst Madhu Kumar lowered his price target for Dicerna Pharmaceuticals to $10 from $13.50 following the company's secondary offering. The shares are "priced for perfection" ahead of Phyox full data for DCR-PHXC in Q4, Kumar tells investors in a research note. He keeps a Neutral rating on the shares.
10/05/18
SBSH
10/05/18
NO CHANGE
SBSH
Gilead may need Dicerna after Arrowhead, J&J deal, says Citi
Given the partnership announced yesterday between Arrowhead Pharmaceuticals (ARWR) and Johnson & Johnson (JNJ), Gilead Sciences' (GILD) hepatitis B virus portfolio may need another component and Dicerna Pharmaceuticals (DRNA) "could be one of them," Citi analyst Robyn Karnauskas tells investors in a research note. The analyst believes large pharma and Gilead are "still missing a key piece to bring a curative therapy to market that can rapidly and effectively lower HBsAg." The Arrowhead deal makes it apparent that HBV portfolios may need a multi-target approach and validates the RNAi platform to target HBV, the analyst contends.
DNA Bought by RHHBY
$0.00

(0.00%)

FOLD Amicus
$11.58

0.63 (5.75%)

05/08/18
JPMS
05/08/18
NO CHANGE
JPMS
Amicus lower on Pompe program commentary, says JPMorgan
JPMorgan analyst Anupam Rama attributes today's post-earnings weakness in shares of Amicus Therapeutics to "conservative commentary" on the call related to the Pompe program. The analyst, however, does not believe that the regulatory scenarios he outlined last month for the program have fundamentally changed. Nonetheless, Rama thinks commentary on the call, particularly on timing, was perceived as cautious. Amicus shares are down 7.5% to $13.49 in midday trading.
04/11/18
JPMS
04/11/18
NO CHANGE
JPMS
Overweight
Amicus risk/reward favorable into regulatory update, says JPMorgan
JPMorgan analyst Anupam Rama notes that a regulatory update for Amicus Therapeutics' Pompe program is expected in Q2. The analyst continues to like the reward/risk profile of the shares going into the update. An accelerated approval path forward is "very much on the table," based on the strength of the Phase 1/2 data, Rama tells investors in a research note. He sees "more win scenarios than lose." The analyst believes Amicus shares can rally 30%-50% should an accelerated approval path forward emerge. Rama keeps an Overweight rating on Amicus with a $19 price target.
08/17/18
CHDN
08/17/18
DOWNGRADE
CHDN
Neutral
Amicus downgraded to Neutral from Buy at Chardan
GSK GlaxoSmithKline
$39.32

-0.2 (-0.51%)

10/08/18
GUGG
10/08/18
INITIATION
GUGG
Neutral
GlaxoSmithKline initiated with a Neutral at Guggenheim
Guggenheim analyst Seamus Fernandez started GlaxoSmithKline with a Neutral rating and 1,679p price target, stating that he views its upside more in the consumer side than in pharma. The company's oncology and immunology pipeline could emerge, but it is still a bit early to tell, Fernandez added in his initiation note.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
GlaxoSmithKline reinitiated with a Peer Perform at Wolfe Research
Wolfe Research analyst Time Anderson reinitiated GlaxoSmithKline with a Peer Perform.
KERX Acquired by AKBA 12/18
$3.02

-0.03 (-0.98%)

08/23/18
HCWC
08/23/18
NO CHANGE
HCWC
Keryx, Akebia merger remains on track, says H.C. Wainwright
H.C. Wainwright analyst Jason Kolbert believes the merger between Keryx Biopharmaceuticals (KERX) and Akebia Therapeutics (AKBA) remains on track. According to the Federal Trade Commission website, the status of the merger application now shows "granted," Kolbert tells investors in a research note. The analyst says that while he did not expect FTC clearance to be an issue, "it's good to see it granted." He keeps a Buy rating on Keryx with a $9 price target.
07/12/18
PIPR
07/12/18
NO CHANGE
Target $22
PIPR
Overweight
Piper incrementally positive on Akebia shares, ups target to $22
Piper Jaffray analyst Christopher Raymond is incrementally positive on shares of Akebia Therapeutics after new nephrologist survey data indicated that Auryxia "has not just turned a corner, but is really on quite a roll, both in terms of the drug's perception and its market share dynamics." With the stock down 4% since before last month's merger announcement with Keryx (KERX), Raymond sees a "significant opportunity" to own Akebia before the drug's near-term share gains and the "real potential of a nephrology powerhouse with both Auryxia and vadadustat, become more apparent." He raised his price target for the shares to $22 from $20 and keeps an Overweight rating on the name.
07/03/18
MZHO
07/03/18
NO CHANGE
Target $21
MZHO
Buy
Akebia merger with Keryx strategically positive, says Mizuho
Mizuho analyst Difei Yang likes Akebia Therapeutics' (AKBA) merger with Keryx Biopharmaceuticals (KERX) from a "strategic and financial standpoint over time." The companies' products are complementary and will provide multiple avenues of value creation for the "new" Akebia, Yang tells investors in a research note. The analyst lowered his price target for Akebia to $21 from $24 and keeps a Buy rating on the shares.
06/28/18
PIPR
06/28/18
NO CHANGE
Target $20
PIPR
Overweight
Akebia tie-up with Keryx makes good long-term sense, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond urges patience despite today's negative reaction to Akebia's (AKBA) merger of equals with Keryx (KERX) as he thinks the combination to create a fully integrated, renal-focused pharma company makes good strategic sense over the long-term and he believes the deal will be received much better by clinicians and other stakeholders than it has been so far by investors. The announcement was also complicated by the coincident disclosure of a delay to vadadustat's data, but Raymond does not think it detracts from the probability of success for the drug. He lowered his price target on Akebia shares to $20 from $23 and keeps an Overweight rating on the stock, which is down 10% to $9.28 in afternoon trading.
MNK Mallinckrodt
$25.61

-0.31 (-1.20%)

10/03/18
BMOC
10/03/18
NO CHANGE
Target $37
BMOC
Outperform
Approval of Noxivent has mitigating factors for Mallinckrodt, says BMO Capital
BMO Capital analyst Gary Nachman kept his Outperform rating and $37 price target on Mallinckrodt (MNK), saying the FDA's approval of Praxair (PX) ANDA for Noxivent, which is a generic form of gas used in the Inomax device for "treating neonates with respiratory failure", has some mitigating factors. The analyst notes that Praxair's device will still have to be approved by the FDA and litigation appeal between the two companies regarding Inomax patents is still ongoing until the first half of next year, with the possibility of a favorable settlement between the two still possible. Moreover, Nachman points to Mallinckrodt's "very strong relationships" with partner hospitals' NICUs, as 25% of its U.S. book of business has been committed for the next couple of years.
10/04/18
STFL
10/04/18
NO CHANGE
Target $30
STFL
Hold
Mallinckrodt selloff today on Praxair ANDA an overreaction, says Stifel
Mallinckrodt (MNK) shares are down sharply this morning following abbreviated new drug application approval of Praxair's (PX) Noxivent, Stifel analyst Annabel Samimy tells investors in a research note. Noxivent's filing as a generic has given investors pause that the gas will be used as a substitute to Mallinckrodt's nitrous oxide in the INOmax System - the leading nitric oxide vasodilator for respiratory failure in term/near-term infants, the analyst says. However, Samimy points out that Noxivent cannot be interchanged with the nitric oxide gas used in the INOmax System, and that thus far, we have not seen a 510(k) approval from the FDA for Praxair's device. Further, the analyst adds that the pending Praxair system will be another branded competitor and not a generic substitute, which she think's today's selloff implies. The analyst also believes consensus estimates have reflected potential competition for well over a year. As such, Samimy thinks today's selloff in Mallinckrodt is overreaction to a "known event". She believes Mallinckrodt is "well-positioned to defend its share." The analyst, nonetheless, keeps a Hold rating on the stock with a $30 price target. The shares in afternoon trading are down 17%, or $5.18, to $25.95.
10/05/18
JEFF
10/05/18
NO CHANGE
Target $35
JEFF
Buy
Mallinckrodt 17% selloff yesterday 'well overdone,' says Jefferies
Jefferies analyst Anthony Petrone views the 17% selloff yesterday in shares of Mallinckrodt (MNK) as "well overdone." The pullback on Praxair's (PX) abbreviated new drug application clearance of Noxivent effectively prices in a $130M revenue shortfall on Mallinckrodt's INOmax in the near term, Petrone tells investors in a research note. Conversely, the analyst expects a more gradual erosion given the ongoing patent appeal process, potential label extension on INOmax, and the need for infrastructure investment on the part of Praxair. He keeps a Buy rating on Mallinckrodt with a $35 price target.
10/08/18
10/08/18
NO CHANGE
Target $24

Market Perform
Wells cuts Mallinckrodt target to $24 after confirming Praxair generic approval
Wells Fargo analyst David Maris says he confirmed this morning with Praxair (PX) that the device associated with generic Inomax has been approved. Praxair would not provide any additional details around the launch timing or pricing plans, Maris tells investors in a research note. The analyst lowered his price target for Mallinckrodt (MNK) shares to $24 from $30 after reducing his estimates to account for the generic taking approximately 20% share over the next several years. He models Mallinckrodt's Inomax going from a 5% grower to a slight decline. Maris admits, however, that there are "strong reasons" to think Inomax has a more defensible position than losing 20% share, such as a loyal installed base and a high service level. Nonetheless, he believes uncertainty around the generic device approval warrant a reduced outlook. The analyst keeps a Market Perform rating on Mallinckrodt. The stock in morning trading is down 5c to $25.83.
NXTM NxStage Medical
$27.89

0.03 (0.11%)

04/05/18
CHLM
04/05/18
NO CHANGE
Target $30
CHLM
Hold
CVS focusing on home dialysis positive for NxStage Medical, says Craig-Hallum
Craig-Hallum analyst Kevin Ellich notes that CVS Health (CVS) announced an initiative to improve patient outcomes for chronic kidney disease and dialysis. The analyst believes that a company of CVS Health's size and stature focusing on home dialysis and specifically home hemodialysis is a positive for NxStage Medical (NXTM) since it is the market leader with a huge head start. While there could be concerns about price competition if and when CVS Health is able to get a home hemodialysis device to market, NxStage Medical will have its next generation products to market, as well as a peritoneal dialysis machine, he contends, adding that he thinks the market opportunity will be much larger. Ellich reiterates a Hold rating and $30 price target on NxStage Medical's shares.
OMER Omeros
$16.17

-0.18 (-1.10%)

10/15/18
HCWC
10/15/18
NO CHANGE
Target $34
HCWC
Buy
Omeros selloff on data brings attractive entry point, say H.C. Wainwright
Data released earlier this month from a Phase 2 trial of OMS721, Omeros's most advanced clinical candidate, appear to have created some confusion in the market as the company's share price has fallen roughly 50% since the announcement, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The selloff is unwarranted, says the analyst, who reiterates a Buy rating on the shares with a $34 price target. He points out that the data were from a small trial that was not designed to deliver statistical significance or definitive evidence of efficacy. Further, the "data itself were encouraging, not discouraging, and there certainly was no evidence of any safety concern or toxicity issue that would have jeopardized OMS721's future development," Selvaraju writes.
07/12/18
GHSC
07/12/18
INITIATION
Target $30
GHSC
Buy
Omeros initiated with a Buy at Seaport Global
Seaport Global analyst Corey Davis initiated Omeros with a Buy and $30 price target saying Omidria for cataract surgery regains pass-through starting October 1 following new legislation. Davis expects the company to quickly return to an annualized run-rate of $87M, and if it secures permanent reimbursement from CMS, likely $200M-$400M in peak sales.
03/23/18
HCWC
03/23/18
NO CHANGE
Target $34
HCWC
Buy
Omeros price target raised to $34 from $30 at H.C. Wainwright
H.C. Wainwright analyst Raghuram Selvaraju raised his price target for Omeros to $34 after Omidria pass-through reimbursement status was extended. The language in the spending bill provides the extension for a period of two years, Selvaraju tells investors in a research note. This is an "unexpected success" for Omeros, and should lead to a "significant rebound" in Omidria sales and resumption of growth in the franchise, Selvaraju writes. He reiterates a Buy rating on Omeros shares.
03/23/18
WEDB
03/23/18
DOWNGRADE
Target $19
WEDB
Neutral
Omeros downgraded to Neutral from Outperform at Wedbush
Wedbush analyst Liana Moussatos downgraded Omeros to Neutral and lowered her price target for the shares to $19 from $47. The analyst sees a "lack of clarity for the financial status" with disruption in Omidria sales and the company's inability to fund progress with its top potential value driver OMS721. Even with possible extension of Omidria pass-through reimbursement for two additional years starting in October 2018, sales are unlikely to fund the pipeline in 2018 and 2019, Moussatos tells investors in a research note. Omeros closed yesterday up 35%, or $4.11, to $15.75.
QDEL Quidel
$62.64

-1 (-1.57%)

09/10/18
ADAM
09/10/18
NO CHANGE
Target $80
ADAM
Buy
Quidel could draw interest from a larger company, says Canaccord
Canaccord analyst Mark Massaro remains positive on Quidel (QDEL) after hosting meetings with management. The analyst cited rising demand for its new products and he expects the company to continue to take market share from larger companies Alere (ABT) and Becton Dickinson (BDX). He also believes the company could draw interest from a larger company, like the bid Alere got from Abbott. Massaro reiterated his Buy rating and raised his price target to $80 from $78 on Quidel shares.
08/08/18
CHLM
08/08/18
NO CHANGE
Target $80
CHLM
Buy
Quidel price target raised to $80 from $64 at Craig-Hallum
Craig-Hallum analyst Alexander Nowak raised his price target for Quidel to $80 from $64 after another quarter of "solid" cardiac execution. However, the analyst notes that the upside was offset by lower Rapid Immunoassay sales, particular lower influenza revenue. He reiterates a Buy rating on the shares.
08/08/18
PIPR
08/08/18
NO CHANGE
Target $74
PIPR
Overweight
Quidel price target raised to $74 from $66 at Piper Jaffray
Piper Jaffray analyst William Quirk raised his price target for Quidel to $74 saying the in-line sales and earnings beat in Q2 does not tell the entire story. The acquired Cardiac business was well ahead of expectations and suggests further upside over the course of 2018, Quirk tells investors in a post-earnings research note. The analyst views the Q2 report as solid and reiterates an Overweight rating on Quidel.
10/23/18
RAJA
10/23/18
INITIATION
Target $80
RAJA
Strong Buy
Quidel resumed with a Strong Buy at Raymond James
Raymond James analyst John Hsu resumed coverage on Quidel with a Strong Buy and $80 price target telling investors it is one of the last remaining pure play diagnostics companies with a focus on point-of-care testing, and it has multiple tailwinds driving sustained mid-single-digit organic growth.
RGLS Regulus
$1.90

-0.1 (-5.00%)

03/27/18
RILY
03/27/18
INITIATION
Target $1
RILY
Neutral
Regulus initiated with a Neutral at B. Riley FBR
B. Riley FBR analyst Madhu Kumar started Regulus Therapeutics with a Neutral rating and $1 price target. The analyst believes the company is facing uncertainty in orphan kidney disease.
07/06/18
WELS
07/06/18
NO CHANGE
Target $0.5
WELS
Market Perform
Regulus price target lowered to 50c from $1.50 at Wells Fargo
Wells Fargo analyst Jim Birchenough lowered his price target for Regulus Therapeutics to the company's approximate cash level of 50c following the interruption of the Phase 1 study of anti-miR therapeutic RGLS4326 in autosomal dominant polycystic kidney disease due to unexpected preclinical toxicity and need for additional preclinical work. With "limited cash runway and continued unpredictable effects of its anti-miR therapeutic candidates," the analyst sees continued overhang and need to monetize earlier pipeline assets to support a recovery in shares of Regulus. He keeps a Market Perform rating on the name.
07/10/18
WEDB
07/10/18
DOWNGRADE
WEDB
Neutral
Regulus downgraded to Neutral from Outperform at Wedbush
07/10/18
07/10/18
DOWNGRADE
Target $1

Neutral
Regulus downgraded to Neutral at Wedbush
As previously reported, Wedbush analyst Liana Moussato downgraded Regulus (RGLS) to Neutral from Outperform after he extended developmental timelines due to partnership restructuring with Sanofi (SNY) pausing clinical enrollment for RG-012 and unexpected mouse toxicity observations delaying clinical progress for RGLS4326. The analyst also lowered his price target on Regulus shares to $1 from $3.
RTRX Retrophin
$24.99

0.32 (1.30%)

04/19/18
HCWC
04/19/18
NO CHANGE
Target $182
HCWC
Buy
H.C. Wainwright reiterates Buy on Ligand after Novartis reports Q1
H.C. Wainwright analyst Joseph Pantginis says the Promacta franchise remains strong after Ligand Pharmaceuticals (LGND) partner Novartis (NVS) reported Q1 sales Promacta revenue of $257M. The analyst projects 2018 is the year that Promacta officially reaches blockbuster status, or $1B in sales. Further, he points out that Retrophin (RTRX), another Ligand partner, earlier this month announced that the first patient has been enrolled into the Phase 3 Duplex study using sparsentan to treat patients with focal segmental glomerulosclerosis. Pantginis is encouraged by the start of the Phase 3 saying it has the potential to lock in a fixed 9% royalty to Ligand, if approved. He currently project peak sales of $825M but feels the drug could reach blockbuster status based on its first-to-market status. Pantginis keeps a Buy rating on Ligand Pharmaceuticals with a $182 price target.
08/17/18
ADAM
08/17/18
INITIATION
Target $36
ADAM
Buy
Retrophin initiated with a Buy at Canaccord
Canaccord analyst Michelle Gilson initiated Retrophin with a Buy rating citing what she views as an attractive valuation given the upside potential provided by the clinical stage pipeline. She sees limited downside risk but upside catalysts with POC data for CNSA-001 in early 2019 and Phase 3 FORT data in PKAN in the second half 2019. Gilson has a $36 price target on Retrophin shares.
AKBA Akebia
$8.06

-0.06 (-0.74%)

10/22/18
MZHO
10/22/18
NO CHANGE
Target $17
MZHO
Buy
Akebia 'significantly undervalued' ahead of catalysts, says Mizuho
Mizuho analyst Difei Yang views Akebia Therapeutics as "significantly undervalued" ahead of catalysts expected in 2019 including data readouts from vadadustat and launch metrics from Auryxia. The stock is one to pay attention to in 2019 following poor performance in 2018 "despite making progress in multiple pivotal trials," Yang tells investors in a research note. She lowered her price target for the shares to $17 from $21 and keeps a Buy rating on Akebia.
09/07/18
MSCO
09/07/18
INITIATION
Target $9
MSCO
Equal Weight
Akebia resumed with an Equal Weight at Morgan Stanley
Morgan Stanley analyst David Lebowitz resumed coverage of Akebia (AKBA) with an Equal Weight rating and $9 price target, stating that value is primarily driven by the potential of vadadustat as a treatment for anemia associated with chronic kidney disease. Vadadustat is a year behind FibroGen's (FGEN) competing HIF-inhibitor roxadustat and that lead could be an advantage if the data for the two drugs is not sufficiently differentiated, said Lebowitz.
08/14/18
08/14/18
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Hudbay Minerals (HBM) reinstated with a Neutral at BofA/Merrill. 2. Establishment Labs (ESTA) initiated with a Buy at BTIG and Jefferies and an Outperform at Cowen. 3. Yext (YEXT) initiated with a Buy at SunTrust. 4. Akebia (AKBA) initiated with an Outperform at Raymond James. 5. Replimune Group (REPL) was initiated with an Outperform at Leerink and BMO Capital as well as an Overweight at JPMorgan. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
SNY Sanofi
$42.62

-0.45 (-1.04%)

10/23/18
WOLF
10/23/18
INITIATION
WOLF
Peer Perform
Sanofi reinitiated with a Peer Perform at Wolfe Research
10/17/18
JEFF
10/17/18
NO CHANGE
Target $31
JEFF
Buy
Jefferies still sees 'major' opportunity for Optinose after Dupixent data
Optinose (OPTN) shares underperformed yesterday following the positive Phase 3 results for Sanofi (SNY) and Regeneron's (REGN) Dupixent in treating patients with chronic rhinosinusitis with nasal polyps, Jefferies analyst David Steinberg tells investors in a research note titled "Biologics Competitor as Expected; Real World Pricing Issues Likely to Limit Us." The analyst says that while Dupixent demonstrated strong efficacy, clinicians he's spoken with believe that the "massive" pricing disparity versus nasal steroids will likely result in payer "step edits" that could limit widespread adoption of the "expensive" biologics currently under development. Further, Dupixent's head-to-head comparison with Optinose's Xhance's "strong" efficacy profile is difficult, the analyst adds. Steinberg still sees a "major" long-term opportunity for Xhance and keeps a Buy rating on Optinose with a $31 price target.

TODAY'S FREE FLY STORIES

TCEHY

Tencent

$0.00

(0.00%)

12:59
01/19/19
01/19
12:59
01/19/19
12:59
Periodicals
Tencent not the best opportunity out there right now, Barron's says »

After securing a billion…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAESY

BAE Systems

$0.00

(0.00%)

12:53
01/19/19
01/19
12:53
01/19/19
12:53
Periodicals
Bae Systems will mount new charge, Barron's says »

Bae Systems has been…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

, COST

Costco

$213.59

2.15 (1.02%)

12:50
01/19/19
01/19
12:50
01/19/19
12:50
Periodicals
Costco might be 'good buy' following 2018 pullback, Barron's says »

Part of what makes Costco…

AMZN

Amazon.com

$1,696.01

4.01 (0.24%)

COST

Costco

$213.59

2.15 (1.02%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Jan

  • 31

    Jan

  • 20

    Feb

  • 03

    Mar

VNO

Vornado

$66.40

1.04 (1.59%)

, KRC

Kilroy Realty

$68.23

0.21 (0.31%)

12:45
01/19/19
01/19
12:45
01/19/19
12:45
Periodicals
Kilroy, Vornado Realty have 'solid' prospects, Barron's says »

Office REITs have been…

VNO

Vornado

$66.40

1.04 (1.59%)

KRC

Kilroy Realty

$68.23

0.21 (0.31%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Feb

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

, GG

Goldcorp

$10.37

0.04 (0.39%)

12:41
01/19/19
01/19
12:41
01/19/19
12:41
Periodicals
Gold mining stocks 'an unalloyed bargain,' Barron's says »

Two multibillion-dollar…

GOLD

Barrick Gold

$11.78

-0.11 (-0.93%)

GG

Goldcorp

$10.37

0.04 (0.39%)

NEM

Newmont Mining

$31.77

0.15 (0.47%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Feb

TECH

Bio-Techne

$163.24

1.16 (0.72%)

, A

Agilent

$71.93

1.16 (1.64%)

12:29
01/19/19
01/19
12:29
01/19/19
12:29
Periodicals
Rising demand benefiting Illumina, Thermo Fisher, Barron's says »

Healthy funding and…

TECH

Bio-Techne

$163.24

1.16 (0.72%)

A

Agilent

$71.93

1.16 (1.64%)

DHR

Danaher

$107.43

1.88 (1.78%)

TMO

Thermo Fisher

$240.72

2.55 (1.07%)

ILMN

Illumina

$312.66

2.53 (0.82%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 29

    Jan

  • 29

    Jan

  • 30

    Jan

  • 30

    Jan

  • 05

    Feb

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

, EA

Electronic Arts

$92.50

3.19 (3.57%)

12:22
01/19/19
01/19
12:22
01/19/19
12:22
Periodicals
EA, Activision struggling to survive a Fortnite World, Barron's says »

Netflix (NFLX) delivered…

ATVI

Activision Blizzard

$48.64

1.26 (2.66%)

EA

Electronic Arts

$92.50

3.19 (3.57%)

NFLX

Netflix

$339.20

-14.02 (-3.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 12

    Feb

  • 25

    Feb

AIMT

Aimmune

$22.90

0.26 (1.15%)

, CELG

Celgene

$86.27

-0.32 (-0.37%)

09:01
01/19/19
01/19
09:01
01/19/19
09:01
On The Fly
Week in review: How Trump's policies moved stocks »

Catch up on the top…

AIMT

Aimmune

$22.90

0.26 (1.15%)

CELG

Celgene

$86.27

-0.32 (-0.37%)

BIIB

Biogen

$337.46

-0.93 (-0.27%)

CMRE

Costamare

$4.97

0.09 (1.84%)

DAC

Danaos

$0.90

0.05 (5.88%)

DCIX

Diana Containerships

$0.90

-0.02 (-2.17%)

TGH

Textainer

$13.34

0.57 (4.46%)

NM

Navios Maritime

$2.73

-0.04 (-1.44%)

YRCM

Rogers Cantel

$0.00

(0.00%)

EXPD

Expeditors

$69.34

1.43 (2.11%)

LEN

Lennar

$44.11

-0.64 (-1.43%)

KBH

KB Home

$20.30

-0.28 (-1.36%)

PHM

PulteGroup

$26.58

-0.27 (-1.01%)

Z

Zillow

$33.93

0.35 (1.04%)

ZG

Zillow

$33.74

0.35 (1.05%)

RLGY

Realogy

$18.27

-0.155 (-0.84%)

RDFN

Redfin

$18.49

0.48 (2.67%)

DDAIF

Daimler AG

$0.00

(0.00%)

FCAU

Fiat Chrysler

$16.78

0.16 (0.96%)

F

Ford

$8.59

0.23 (2.75%)

GM

General Motors

$38.63

0.35 (0.91%)

HMC

Honda

$29.77

0.22 (0.74%)

NSANY

Nissan

$0.00

(0.00%)

TM

Toyota

$125.40

0.505 (0.40%)

VLKAY

Volkswagen

$0.00

(0.00%)

VC

Visteon

$76.43

4.85 (6.78%)

ADNT

Adient

$19.78

1.59 (8.74%)

AXL

American Axle

$14.62

0.45 (3.18%)

DLPH

Delphi Technologies

$15.94

0.44 (2.84%)

APTV

Aptiv

$72.91

1.77 (2.49%)

BWA

BorgWarner

$40.60

0.54 (1.35%)

LEA

Lear

$151.67

0.98 (0.65%)

TEN

Tenneco

$34.61

1.125 (3.36%)

MGA

Magna

$50.91

0.78 (1.56%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

  • 25

    Jan

  • 29

    Jan

  • 29

    Jan

  • 31

    Jan

  • 06

    Feb

  • 07

    Feb

  • 14

    Feb

  • 19

    Feb

  • 25

    Apr

  • 18

    May

  • 28

    May

  • 24

    Jul

  • 23

    Oct

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

, FPRX

Five Prime

$11.20

0.53 (4.97%)

04:55
01/19/19
01/19
04:55
01/19/19
04:55
Conference/Events
American Society of Clinical Oncology to hold a symposium »

ASCO GI 2019 Symposium…

ASLN

Aslan Pharmaceuticals

$3.55

(0.00%)

FPRX

Five Prime

$11.20

0.53 (4.97%)

KURA

Kura Oncology

$15.70

-0.06 (-0.38%)

ZLAB

Zai Lab

$25.98

-0.05 (-0.19%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

04:55
01/19/19
01/19
04:55
01/19/19
04:55
Conference/Events
Deutsche Bank to hold a conference »

17th Annual dbAccess…

TCCO

Technical Comm Corp

$2.61

-0.19 (-6.79%)

18:02
01/18/19
01/18
18:02
01/18/19
18:02
Hot Stocks
Technical Comm Corp reports notice of failure to satisfy Nasdaq rule »

Technical Communications…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$6.19

0.455 (7.93%)

17:38
01/18/19
01/18
17:38
01/18/19
17:38
Periodicals
Snap exec fired due to undisclosed relationship with consultant, Cheddar says »

Snap's global…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

  • 05

    Feb

  • 03

    Mar

SSW

Seaspan

$9.16

0.16 (1.78%)

17:33
01/18/19
01/18
17:33
01/18/19
17:33
Syndicate
Breaking Syndicate news story on Seaspan »

Seaspan files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TXT

Textron

$49.38

0.75 (1.54%)

17:30
01/18/19
01/18
17:30
01/18/19
17:30
Hot Stocks
Textron subsidiary awarded $439.56M government contract modification »

Bell Helicopter Textron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jan

TAC

TransAlta

$4.91

0.04 (0.82%)

17:28
01/18/19
01/18
17:28
01/18/19
17:28
Hot Stocks
Mangrove Partners reports 9.4% passive stake in TransAlta »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TDS

Telephone and Data

$36.27

0.42 (1.17%)

17:27
01/18/19
01/18
17:27
01/18/19
17:27
Hot Stocks
Telephone and Data's Meyers sells 80,465 common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GWPH

GW Pharmaceuticals

$137.24

2.59 (1.92%)

17:03
01/18/19
01/18
17:03
01/18/19
17:03
Syndicate
Breaking Syndicate news story on GW Pharmaceuticals »

GW Pharmaceuticals files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCSC

Fibrocell Science

$2.03

0.03 (1.50%)

16:55
01/18/19
01/18
16:55
01/18/19
16:55
Syndicate
Breaking Syndicate news story on Fibrocell Science »

Fibrocell Science files…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

, ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Conference/Events
EnLink Midstream Partners to hold a special shareholder meeting »

Special Shareholder…

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

FDX

FedEx

$176.97

3.72 (2.15%)

16:49
01/18/19
01/18
16:49
01/18/19
16:49
Hot Stocks
FedEx establishes voluntary buyout program for U.S. workers »

FedEx said in a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Jan

  • 31

    Jan

  • 03

    Mar

  • 19

    Mar

  • 01

    Apr

  • 02

    Apr

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

, ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

16:48
01/18/19
01/18
16:48
01/18/19
16:48
Conference/Events
EnLink Midstream Companies to hold a special shareholder meeting »

Special Shareholder…

ENLK

EnLink Midstream Partners

$13.58

0.51 (3.90%)

ENLC

EnLink Midstream

$11.75

0.4 (3.52%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 23

    Jan

MKL

Markel

$1,067.03

13.52 (1.28%)

16:36
01/18/19
01/18
16:36
01/18/19
16:36
Hot Stocks
Markel says Anthony Belisle, Alissa Fredricks no longer with company »

Markel Corporation said…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NILSY

Norilsk Nickel

$0.00

(0.00%)

16:35
01/18/19
01/18
16:35
01/18/19
16:35
Downgrade
Norilsk Nickel rating change at Goldman Sachs »

Norilsk Nickel downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

, ABBV

AbbVie

$89.51

2.28 (2.61%)

16:33
01/18/19
01/18
16:33
01/18/19
16:33
Hot Stocks
AbbVie: Phase 3 study of ibrutinib did not meet primary endpoint »

AbbVie (ABBV) announced…

JNJ

Johnson & Johnson

$130.65

1.54 (1.19%)

ABBV

AbbVie

$89.51

2.28 (2.61%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jan

  • 25

    Jan

  • 27

    Jan

  • 28

    Jan

  • 18

    Feb

  • 18

    May

FOMX

Foamix

$3.70

-0.14 (-3.65%)

16:32
01/18/19
01/18
16:32
01/18/19
16:32
Conference/Events
Foamix to host research and development day »

Research and Development…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 24

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.